Los mármoles comerciales “Marrón Imperial” y “Marrón Emperador” (S.E. España). Caracterización petrológica y criterios de exploración

Los mármoles comerciales "Marrón Imperial" y "Marrón Emperador" son dolomías brechoides que de acuerdo con la clasificación del MIA pertenece al Grupo C de mármoles comerciales. Se determinan sus parámetros petrofísicos según la norma UNE. Sus rasgos petrológicos se estudian mediante microscopio petrográfico de luz transmitida y microscopio electrónico de barrido (MEB) (en modo de electrones secundarios y electrones retrodispersados). Estas rocas son básicamente dolomías mesocristalinas con abundantes vénulas calcíticas politexturales relacionadas con procesos de brechificación y de dolomitización. Rasgos kársticos aumentan la complejidad petrológica de estas rocas ornamentales cuyo litosoma son las dolomías masivas del Cretácico Superior (¿Turoniense?) del dominio Prebético Externo. El material explotado pertenece a una alineación morfoestructural que va desde Jumilla hasta el NE de Caudete y está relacionado con la falla Jumilla-Yecla-Caudete-Font de la Figuera. La relación entre esta falla y las dolomías turonienses son el principal criterio de exploración de estas rocas ornamentales.The "Marrón Imperial" and the "Marrón Emperador" commercial marble are brecciated dolomite rocks that, in agree with the soundness classification of MIA, belongs to the Group C of the commercial marbles. Petrophysical parameters of stones has been obtained using de UNE NORM (Spanish normalised test). The petrologic features have been defined from light microscopy and SEM data (secondary electrons and back scattered electrons modes). "Marrón Imperial" and "Marrón Emperador" are mesocrystalline dolostones with a reticulate of calcite veins, which are polytextural and are related to both brecciation and dedolomitization processes. Karstic features increase the petrologic complexity of this dimensional stone. The host lithosomes of "Marrón Imperial" and "Marrón Emperador" marbles are the massive dolostones of Upper Cretaceous (Turonian?) age of Outer Prebetic Domain. The quarried material outcrops from Jumilla to NE Caudete; Villena-La Encina, Jumilla (Fuente and Cingla Mountains) Yecla (Magdalena Mountains). Caudete and Yecla are the most important areas for extraction at the moment. The tectofacies that are the main responsible of the aesthetic properties of the Marrón Imperial and Marrón Emperador commercial marbles which main outcrops are probably related to the Jumilla-Yecla-Caudete-Font de la Figuera near strike-slip fault and associated events. The main exploration criteria from this type of commercial marble are the fault line distribution, and their influence over Turonian dolostones.Este trabajo forma parte del Proyecto AMB 93-0019 subvencionado por la CICYT

Blood RNA sequencing reveals immunological processes associated with the response to abatacept in rheumatoid arthritis.

Resume

Negative symptoms and sex differences in first episode schizophrenia: What's their role in the functional outcome? A longitudinal study

Introduction: Negative symptoms (NS) include asociality, avolition, anhedonia, alogia, and blunted affect and are linked to poor prognosis. It has been suggested that they reflect two different factors: diminished expression (EXP) (blunted affect and alogia) and amotivation/pleasure (MAP) (anhedonia, avolition, asociality). The aim of this article was to examine potential sex differences among first-episode schizophrenia (FES) patients and analyze sex-related predictors of two NS symptoms factors (EXP and MAP) and functional outcome. Material and methods: Two hundred and twenty-three FES (71 females and 152 males) were included and evaluated at baseline, six-months and one-year. Repeated measures ANOVA was used to examine the effects of time and sex on NS and a multiple linear regression backward elimination was performed to predict NS factors (MAP-EXP) and functioning. Results: Females showed fewer NS (p = 0.031; Cohen's d = −0.312), especially those related to EXP (p = 0.024; Cohen's d = −0.326) rather than MAP (p = 0.086), than males. In both male and female group, worse premorbid adjustment and higher depressive symptoms made a significant contribution to the presence of higher deficits in EXP at one-year follow-up, while positive and depressive symptoms predicted alterations in MAP. Finally, in females, lower deficits in MAP and better premorbid adjustment predicted better functioning at one-year follow-up (R2 = 0.494; p < 0.001), while only higher deficits in MAP predicted worse functioning in males (R2 = 0.088; p = 0.012). Conclusions: Slightly sex differences have been found in this study. Our results lead us to consider that early interventions of NS, especially those focusing on motivation and pleasure symptoms, could improve functional outcomes

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio